MS drug's withdrawal triggers scrutiny of stock sales
B OSTON - The withdrawal of a new multiple sclerosis drug has focused scrutiny on millions of dollars in insider stock sales at Biogen Idec Inc. and executive bonuses approved in the days before the company disclosed a death and illness that led to the drug's removal from the market.
The transactions...
The article you requested has been archived » Click for access to article within the archive * All other coverage within BostonHerald.com from the last 7 days remains free of charge. Articles do not always include original photos, charts or graphics.
Low High Current Rating: This article has not been rated yet Your Rating: Please enable cookies to rate articles
Herald Interactive Tools Herald Columnists Brew ’n’ fans
Fred Olivieri knew he was in for a long evening the moment his inebriated neighbor arrived at Row 4 ... [ more ]
Élan, the largest Irish pharmaceutical company, and its US partner Biogen have withdrawn the multiple sclerosis drug ''Tysabri'' from clinical trials after the death of a patient. The drug was seen by many as a possible blockbuster drug with the potential to alleviate much of the suffering of the millions of multiple sclerosis suffers worldwide. However it is now quite unlikely that it will ever make it to market.

The news has seen the shares of both companies fall steeply, with Élan having lost almost 70% of its value after Monday's announcement. Two years ago Élan was the largest Irish PLC, with a value in excess of $20bn, but an accountancy scandal saw its shares fall from over €73 to €1.50 within a few weeks. Since then the stock had risen back to trade between €16 and €18 a share on the back of good restructuring news. However the withdrawal of ''Tysabri'' leaves Elan with almost no potential future revenue streams.

Biogen shares which had hit a 52 week high of $70 just two weeks before the announcement have since fallen to just $41.26. Combined equity losses on Monday for the two firms was over $17.8 billion.

The paitent who died had been taken in combination with another drug - ''Avonex'' - for the last two years. If it emerges that the death was as a result of taking ''Avonex'', then it is possible ''Tysabri'' could be re-introduced to the market. However for the moment rivals will be seeking to steal a lead in the potentially lucrative MS drug market.